Microfluidics-enabled mesenchymal stem cell derived Neuron like cell membrane coated nanoparticles inhibit inflammation and apoptosis for Parkinson's Disease
T Lei, C Li, Y Liu, Z Cui, S Deng, J Cao, H Yang… - Journal of …, 2024 - Springer
Parkinson's disease (PD) is the second largest group of neurodegenerative diseases, and
its existing drug treatments are not satisfactory. Natural cell membrane drugs are used for …
its existing drug treatments are not satisfactory. Natural cell membrane drugs are used for …
Efficacy and efficacy-influencing factors of stem cell transplantation on patients with Parkinson's disease: a systematic review and meta-analysis
J Zhao, K Qu, S Jia, R Yang, Z Cui, J Li, P Yu… - Frontiers in …, 2024 - frontiersin.org
Background Cell transplants as a treatment for Parkinson's disease have been studied for
decades, and stem cells may be the most promising cell sources for this treatment. We …
decades, and stem cells may be the most promising cell sources for this treatment. We …
Comparing the effect of intravenous versus intracranial grafting of mesenchymal stem cells against parkinsonism in a rat model: Behavioral, biochemical, pathological …
A Essawy Essawy, OA Abou-ElNaga, RA Mehanna… - Plos one, 2024 - journals.plos.org
Parkinson's disease (PD) is one of the most common neurodegenerative diseases
worldwide. Currently applied therapeutic protocols are limited to improve the motor functions …
worldwide. Currently applied therapeutic protocols are limited to improve the motor functions …
Phase 1 study of safety and preliminary efficacy of intranasal transplantation of human neural stem cells (ANGE-S003) in Parkinson's disease
S Jiang, H Wang, C Yang, F Feng, D Xu… - Journal of Neurology …, 2024 - jnnp.bmj.com
Background Intranasal transplantation of ANGE-S003 human neural stem cells showed
therapeutic effects and were safe in preclinical models of Parkinson's disease (PD). We …
therapeutic effects and were safe in preclinical models of Parkinson's disease (PD). We …